# Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research

* Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective cancer treatments.
* Calidi Biotherapeutics has announced preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors.
* The trials show an ability to deliver therapeutic payloads with precision while simultaneously attacking tumors.

 Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by 2050 (https://ibn.fm/VfZlY). These numbers underscore the urgency of ongoing cancer research and the need for more effective cancer treatments.

 This is where cutting-edge innovations, such as those pioneered by Calidi Biotherapeutics (NYSE American: CLDI), come into play. Calidi Biotherapeutics recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/calidi-biotherapeutics-inc-nyse-american-cldi-committed-to-advancing-cancer-care-with-innovative-rtnova-platform-research/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/calidi-biotherapeutics-unveils-breakthrough-in-cancer-treatment-delivery/1d691f11970ef64783cc22c3412d6953) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1kbihcf/calidi_biotherapeutics_unveils_breakthrough_in/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/254/30/chefKt81.webp)